April 22, 2024

Webinar: Automating antibiotic discovery in academia: A collaborative screening effort to identify novel TB therapeutics

Webinar: Automating antibiotic discovery in academia: A collaborative screening effort to identify novel TB therapeutics

In this webinar, hear how a collaboration between SPT Labtech, Automata, GSK, and researchers at the Francis Crick Institute, employed cutting-edge automation tools, including the dragonfly® discovery liquid handling system by SPT Labtech and Automata’s LINQ platform, to conduct a high-throughput enzymatic screen targeting a vulnerable pathway in Mycobacterium tuberculosis (Mtb).

About this webinar

The automation of drug discovery has advanced considerably, driven by the need for enhanced efficiency, reproducibility, and scalability in high-throughput screening workflows. In this study, a collaboration between SPT Labtech, Automata, GSK, and researchers at the Francis Crick Institute, employed cutting-edge automation tools, including the dragonfly® discovery liquid handling system by SPT Labtech and Automata’s LINQ platform, to conduct a high-throughput enzymatic screen targeting a vulnerable pathway in Mycobacterium tuberculosis (Mtb). This effort was part of a broader initiative to discover novel antibiotics against Mtb. 

Tuberculosis (TB), caused by Mtb, remains a global health emergency, with 10.8 million cases and 1.25 million deaths reported in 2023. The rise of drug-resistant strains underscores the urgent need for novel therapeutic approaches. Targeting an essential enzyme in the Mtb amino acid biosynthetic pathway, a repurposing screen of 6,000 compounds was conducted building upon prior GSK efforts targeting the human orthologue. This enabled assessment of potency, selectivity, and microbiological efficacy. 

The findings accelerated the identification of promising Mtb enzyme inhibitors and provided a strong foundation for further medicinal chemistry efforts. Additionally, iterative refinement of the automated workflow provided critical insights into the potential of robotic platform integration for high-throughput drug discovery.

Key learning objectives:

  • Introduce the technical capabilities of the Automata LINQ platform for end-to-end automated biochemical screening and SPT Labtech’s dragonfly® discovery for fast and precise liquid handling. 
  • Applications for laboratory automation in TB drug discovery research.
  • Understanding the development and optimization timeline and workflow for scaling up a time sensitive, kinetic, enzyme assay on an automated high-throughput scale.
  • Explore the challenges and benefits of automation for drug discovery workflows in academia.

 

register now

Our latest News

discover more
TRANSVAC: a pillar of vaccine development in Europe for 16 years

TRANSVAC: a pillar of vaccine development in Europe for 16 years

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the EVI-led TRANSVAC project, an ambitious initiative funded by the European Commission. Since its launch in 2009, TRANSVAC has established itself as a key player in advancing vaccine research, supporting over 160 vaccine projects while fostering innovation and collaboration in […]

Novel analysis of intrinsically disordered proteins

Novel analysis of intrinsically disordered proteins

Researchers from Mainz University and EMBL Hamburg present a new approach for structurally characterising disordered proteins by combining two different analysis methods. Proteins are the molecules that perform most ‘actions’ in the cell, and thus, are key for our body functions. Essentially, proteins are strings of amino acids, which, in most cases, fold like origami […]

Repeated polyp diagnoses in relatives indicate higher risk of colorectal cancer

Repeated polyp diagnoses in relatives indicate higher risk of colorectal cancer

Researchers at the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have investigated the association between an individual’s risk of colorectal cancer and repeated diagnoses of colorectal polyp in relatives. They conclude that, in particular, the risk of developing colorectal cancer at a young age is significantly increased […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp